Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aveanna Healthcare Holdings (AVAH) Gains from Sales and Divestitures (2022 - 2026)

Aveanna Healthcare Holdings posted quarterly Gains from Sales and Divestitures of $5.7 million for Q1 2026, up 728.53% year-on-year from $688865.0 in Q1 2025, and up 728.53% on a QoQ basis from $688865.0 in Q4 2024.

Aveanna Healthcare Holdings (AVAH) has 4 years of Gains from Sales and Divestitures data on file, last reported at $5.7 million in Q1 2026.

  • For the quarter ending Q1 2026, Gains from Sales and Divestitures rose 728.53% year-over-year to $5.7 million; the trailing twelve-month figure through Jan 2026 stood at $5.7 million (up 728.53% YoY), and the FY2026 full-year result was $5.7 million, up 728.53% from the prior year.
  • Gains from Sales and Divestitures for Q1 2026 stood at $5.7 million, up from $688865.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $5.7 million in Q1 2026 and bottomed at $308055.0 in Q4 2023.
  • The 4-year median for Gains from Sales and Divestitures is $504959.0 (2022), against an average of $1.8 million.
  • The widest annual swing landed in 2023, when Gains from Sales and Divestitures retreated 4.05%; it then soared 728.53% in 2026.
  • A 4-year view of Gains from Sales and Divestitures shows it stood at $321053.0 in 2022, then declined by 4.05% to $308055.0 in 2023, then jumped by 123.62% to $688865.0 in 2024, then soared by 728.53% to $5.7 million in 2026.
  • The last three Gains from Sales and Divestitures figures came in at $5.7 million (Q1 2026), $688865.0 (Q4 2024), and $308055.0 (Q4 2023), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 HCA Healthcare 84.64 Bn 87.02 Bn 16.26 Bn
2 Tenet Healthcare 15.22 Bn 14.39 Bn 4.41 Bn
3 Davita 13.10 Bn 13.96 Bn 1.07 Bn
4 Encompass Health 10.50 Bn 11.12 Bn 1.34 Bn
5 Ensign 9.69 Bn 9.09 Bn 293.37 Mn
6 Universal Health Services 8.92 Bn 8.88 Bn 3.21 Bn
7 Fresenius Medical Care AG 7.31 Bn 4.93 Bn 22,843.10 Bn
8 Chemed 5.83 Bn 5.81 Bn 215.76 Mn
9 Pacs 5.76 Bn 5.51 Bn 345.96 Mn
10 Aveanna Healthcare Holdings 1.46 Bn 1.26 Bn 213.30 Mn

Historic Data

Download Data 🔒
DateValue
Jan 3, 2026 5.71 Mn
Jan 3, 2026 5.71 Mn
Dec 28, 2024 688,865.00
Dec 28, 2024 688,865.00
Dec 30, 2023 308,055.00
Dec 30, 2023 308,055.00
Dec 31, 2022 321,053.00
Dec 31, 2022 321,053.00